



## Targeted Therapies for Acute Leukemias

Guest Editor:

**Dr. Eleftheria Hatzimichael**

Department of Hematology,  
Faculty of Medicine, University of  
Ioannina, Stavros Niarchos  
Avenue, 45110 Ioannina, Greece

Deadline for manuscript  
submissions:

**31 December 2024**

### Message from the Guest Editor

Dear Colleagues,

Targeted therapies aim to interfere with the molecular pathways that drive the growth and survival of leukemia cells, while simultaneously mitigating any adverse effects on healthy cells. Several such agents have revolutionized treatment approaches and improved outcomes for many patients with acute leukemias.

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. Recent advances have significantly impacted treatment options.

Acute lymphoblastic leukemia (ALL) is the most common acute leukemia in children. The targeted agents used in B-ALL are tyrosine kinase inhibitors when Philadelphia-positive, rituximab, blinatumomab, inotuzumab, ozogamicin and, most recently, chimeric antigen receptor (CAR)-T cell therapies.

Nevertheless, questions remain about optimal sequencing, effective combinations, maintenance therapy post-remission, especially in AML, and treatment options post-CAR-T cell therapy failure in ALL. This Special Issue focuses on known or developing targeted treatments in acute leukemias to provide clinicians a comprehensive perspective.

Dr. Eleftheria Hatzimichael  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Maurizio Battino**

Department of  
Odontostomatologic and  
Specialized Clinical Sciences,  
Sez-Biochimica, Faculty of  
Medicine, Università Politecnica  
delle Marche, Via Ranieri 65,  
60100 Ancona, Italy

## Message from the Editor-in-Chief

*Diseases* is an international, peer-reviewed, open access, multidisciplinary journal that focuses on the latest outstanding research concerning diseases and conditions. Research articles, reviews, and other contents are released on the Internet immediately after acceptance. This journal aims to cover international conferences and symposia as new targets.

*Diseases* is increasingly gaining acceptance and visibility within scholars, and after only a few years of life, *Diseases* is now also covering specific topics with dedicated special issues. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High visibility:** indexed within Scopus, ESCI (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

**Rapid Publication:** manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.8 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2023).

## Contact Us

*Diseases* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
www.mdpi.com

mdpi.com/journal/diseases  
diseases@mdpi.com  
X@Diseases\_MDPI